Epstein-Barr virus latent membrane protein 2-derived peptides presented on major histocompatibility complex (EBV LMP2-pMHC)

Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) is a viral protein expressed during Latency II and III stages of EBV infection, which are associated with various malignancies such as nasopharyngeal carcinoma and Hodgkin lymphoma. LMP2-derived peptides are processed intracellularly and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, primarily HLA-A*02:01 and HLA-A*11:01. These peptide-MHC (pMHC) complexes serve as critical targets for the host's cellular immune response, specifically cytotoxic T lymphocytes (CTLs). In the context of immunotherapy, these complexes are targeted by TCR-engineered T cells (TCR-T), peptide vaccines, and bispecific T-cell engagers to selectively eliminate EBV-transformed tumor cells. Because LMP2 is a foreign viral protein, it offers a high degree of tumor specificity compared to self-antigens, although its expression is often subdominant. Therapeutic strategies focusing on these pMHC complexes aim to overcome the immune-suppressive environment of EBV-associated tumors and provide a precision medicine approach based on the patient's HLA profile.

Other names

EBV LMP2 peptide-HLA complexLMP2A/B-MHC complexEpstein-Barr virus LMP2 antigenLMP2-derived epitopesLMP2-HLA-A*0201 complex

T-cell receptor (TCR) mediated recognition of the peptide-MHC complex leading to cytotoxic T-lymphocyte activation and lysis of EBV-positive cells.